Company profile TRVI

Trevi Therapeutics Inc
trevi therapeutics, inc. is a late-stage biopharmaceutical company focused on developing nalbuphine® er for chronic pruritic conditions. pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions. the company is pursuing several pruritic conditions for clinical development, including its lead indication of prurigo nodularis. prurigo nodularis ...is a chronic pruritic dermatologic condition characterized by the presence of pruriginous lesions (excoriative/ulcerative papules and nodules) on the skin. there are no approved therapies in the us or eu for this condition. nalbuphine® er is an oral extended release synthetic opioid with a dual mechanism of action, mu receptor antagonist and kappa receptor agonist, both of which have been shown in research to be effective in abolishing itch. because of nalbuphine® er’s unique dual mechanism of action, which has shown efficacy in addressing pruritus in human clinical trials, the company believes nalbuphine® er can Show More
Quarter analysis & expected interest

There is not enough data for Trevi Therapeutics - Company Profile to provide analysis

Correlation between past revenue and Trevi Therapeutics - Company Profile search interest

There is not enough data for Trevi Therapeutics - Company Profile to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Trevi Therapeutics - Company Profile to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Trevi Therapeutics ticker to provide analysis

Correlation between past revenue and Trevi Therapeutics ticker search interest

There is not enough data for Trevi Therapeutics ticker to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Trevi Therapeutics ticker to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Trevi Therapeutics news to provide analysis

Correlation between past revenue and Trevi Therapeutics news search interest

There is not enough data for Trevi Therapeutics news to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Trevi Therapeutics news to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 12:20:50.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
Trevi Therapeutics stock expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
20190
166
inf% QoQ
280
68.7% QoQ
52
-81.4% QoQ
2020 156
inf% YoY 200.0% QoQ
76
-54.2% YoY -51.3% QoQ
89
-68.2% YoY 17.1% QoQ
96
84.6% YoY 7.9% QoQ
2021 123
-21.2% YoY 28.1% QoQ
139
82.9% YoY 13.0% QoQ
39
-56.2% YoY -71.9% QoQ
167
74.0% YoY 328.2% QoQ
2022 72
-41.5% YoY -56.9% QoQ
218
56.8% YoY 202.8% QoQ
114
192.3% YoY -47.7% QoQ
166
-0.6% YoY 45.6% QoQ
2023 120
66.7% YoY -27.7% QoQ
39
-82.1% YoY -67.5% QoQ
38
-66.7% YoY -2.6% QoQ
213
28.3% YoY 460.5% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and Trevi Therapeutics stock search interestLast update: February 09 2024 12:20:50.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 12:20:51.

The average 5 years interest of Trevi Therapeutics stock was 9.05 per week.
The last year interest of Trevi Therapeutics stock compared to the last 5 years has changed by -28.62%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -45.62%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Trevi Therapeutics headquarters to provide analysis

Correlation between past revenue and Trevi Therapeutics headquarters search interest

There is not enough data for Trevi Therapeutics headquarters to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Trevi Therapeutics headquarters to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Haduvio drug to provide analysis

Correlation between past revenue and Haduvio drug search interest

There is not enough data for Haduvio drug to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Haduvio drug to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Haduvio clinical trial to provide analysis

Correlation between past revenue and Haduvio clinical trial search interest

There is not enough data for Haduvio clinical trial to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Haduvio clinical trial to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for chronic pruritus treatment to provide analysis

Correlation between past revenue and chronic pruritus treatment search interest

There is not enough data for chronic pruritus treatment to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for chronic pruritus treatment to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 12:20:57.

After 39 days of this quarter the interest is at 218.0. Based on that we can calculate that during remaining 52 days it will total up to 509.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019337
394
16.9% QoQ
248
-37.1% QoQ
371
49.6% QoQ
2020 415
23.1% YoY 11.9% QoQ
261
-33.8% YoY -37.1% QoQ
372
50.0% YoY 42.5% QoQ
343
-7.5% YoY -7.8% QoQ
2021 264
-36.4% YoY -23.0% QoQ
242
-7.3% YoY -8.3% QoQ
427
14.8% YoY 76.4% QoQ
444
29.4% YoY 4.0% QoQ
2022 410
55.3% YoY -7.7% QoQ
499
106.2% YoY 21.7% QoQ
419
-1.9% YoY -16.0% QoQ
554
24.8% YoY 32.2% QoQ
2023 509
24.1% YoY -8.1% QoQ
490
-1.8% YoY -3.7% QoQ
586
39.9% YoY 19.6% QoQ
743
34.1% YoY 26.8% QoQ
2024 218
-57.2% YoY -70.7% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and chronic cough treatment search interestLast update: February 09 2024 12:20:56.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 12:20:58.

The average 5 years interest of chronic cough treatment was 32.74 per week.
The last year interest of chronic cough treatment compared to the last 5 years has changed by 35.8%.
The interest for chronic cough treatment is trending.
The last year interest is quite higher compared to 5 years ago. It has increased by 52.78%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 18:14:14.

After 39 days of this quarter the interest is at 78.0. Based on that we can calculate that during remaining 52 days it will total up to 182.0.
idiopathic pulmonary fibrosis treatment expected interest is significantly lower compared to previous quarter (-46.3%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019118
135
14.4% QoQ
101
-25.2% QoQ
131
29.7% QoQ
2020 152
28.8% YoY 16.0% QoQ
147
8.9% YoY -3.3% QoQ
289
186.1% YoY 96.6% QoQ
98
-25.2% YoY -66.1% QoQ
2021 182
19.7% YoY 85.7% QoQ
259
76.2% YoY 42.3% QoQ
280
-3.1% YoY 8.1% QoQ
126
28.6% YoY -55.0% QoQ
2022 195
7.1% YoY 54.8% QoQ
119
-54.1% YoY -39.0% QoQ
71
-74.6% YoY -40.3% QoQ
101
-19.8% YoY 42.3% QoQ
2023 184
-5.6% YoY 82.2% QoQ
239
100.8% YoY 29.9% QoQ
216
204.2% YoY -9.6% QoQ
339
235.6% YoY 56.9% QoQ
2024 78
-57.6% YoY -77.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and idiopathic pulmonary fibrosis treatment search interestLast update: February 09 2024 18:14:13.
Correlation coefficient between keyword and revenue is nan
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 18:14:15.

The average 5 years interest of idiopathic pulmonary fibrosis treatment was 13.64 per week.
The last year interest of idiopathic pulmonary fibrosis treatment compared to the last 5 years has changed by 34.38%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 84.04%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TRVI
Earnings date: 2024-03-14 After close
Company name: Trevi Therapeutics Inc
Sector: Manufacturing
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-05-06T12:09:38Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

2026-05-06T11:19:53Z

Analyst Upgrades
Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $23

2026-05-05T20:05:00Z

GlobeNewswire
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

2026-04-30T20:05:00Z

GlobeNewswire
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference

2026-04-28T20:05:00Z

GlobeNewswire
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026

2026-04-23T20:05:00Z

GlobeNewswire
Trevi Therapeutics to Participate in Upcoming May Events

2026-04-20T20:05:00Z

GlobeNewswire
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

2026-04-17T02:42:00Z

GlobeNewswire
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock

2026-04-16T20:08:00Z

GlobeNewswire
Trevi Therapeutics Announces Proposed Public Offering of Common Stock

2026-04-01T11:30:00Z

GlobeNewswire
Trevi Therapeutics to Participate in Upcoming Events

2026-03-18T15:38:13Z

Analyst Upgrades
Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18

2026-03-18T10:05:54Z

Analyst Upgrades
Needham Maintains Buy on Trevi Therapeutics, Raises Price Target to $24

2026-03-10T20:05:00Z

GlobeNewswire
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026

2026-03-09T16:28:43Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on Trevi Therapeutics, Maintains $21 Price Target

2026-03-09T11:30:00Z

GlobeNewswire
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough